Mechanistic determinants of frailty in breast cancer survivors

Authors: Bucchireddigari B, Blew RM, Frye JB, Nicholas JS, Chen Z, Bea JW, Funk JL

Category: Survivorship & Health Outcomes/Comparative Effectiveness Research
Conference Year: 2021

Abstract Body:
Purpose: The expected losses of bone and muscle mass with aging are accelerated by chemotherapy and radiation, increasing frailty risks. Frailty is inversely related to cancer survivorship. Our pre-clinical studies suggest that the enzyme beta-glucuronidase (GUSB) aids in the bioactivation of dietary polyphenols reported to prevent age-related bone and muscle loss. We examined associations between serum GUSB activity, a biomarker of enzyme function, and bone density and muscle mass measures in postmenopausal breast cancer survivors (n = 27; >3 months post-chemotherapy and/or radiation). Methods: Serum GUSB enzyme activity levels were determined using a standard assay. Total body dual-energy x-ray absorptiometry scans assessed skeletal muscle index (SMI, appendicular lean mass [kg]/ height [m2]) and areal bone mineral density (aBMD) of the total hip, using manual region of interest selection for hip aBMD. Backward stepwise regression models assessed the relationship between GUSB and aBMD and, separately, GUSB and SMI. Initial covariates were age, BMI (kg/m2), log C-reactive protein (CRP). Results: The majority of participants were non-Hispanic Caucasians (74%) with a mean age of 57 years (range, 43 to 73) and 6.1 ± 4.6 years post-diagnosis. BMI was 30.02 ± 4.36 kg/m2, aBMD total hip 0.99 ± 0.10 mg/cm2, SMI 6.28 ± 0.59 kg/m2, and GUSB activity 0.85 ± 0.40 U/L. GUSB correlated with SMI, with a standardized beta coefficient of 0.551 (final covariates: BMI, log CRP; Adj. R2 0.510; p < 0.01). GUSB correlated with total hip aBMD, with a standardized beta coefficient of 0.444 (no covariates remained; Adj. R2 0.165; p < 0.05). Conclusion: Associations of GUSB activity levels with muscle and bone mass are consistent with the postulate that low GUSB activity may be a risk factor for increased frailty, leading to worse outcomes in postmenopausal breast cancer survivors. Further studies are required to confirm this finding, including specific consideration of dietary polyphenol intake. Funding Sources: NIH (CA023074, CA217725)

Keywords: breast cancer, GUSB, frailty, bone mass, muscle mass